Five-year mean follow-up of NeoHexa sirolimus eluting coronary stent: A retrospective evaluation of long-term safety and efficacy

Table 1 Baseline patient characteristics, n (%)/mean ± SD

Variables	n = 740 patients
Age in years	55.25 ± 10.00
Gender
Male	612 (82.70)
Female	128 (17.29)
Heart rate (bpm)	80.20 ± 10.57
Blood pressure (mmHg)
Diastolic	77.12 ± 8.57
Systolic	121.8 ± 15.29
Sr creatinine (mg/dL)	1 ± 0.25
eGFR (mL/minute/1.73 m2)	86.36 ± 20.60
Hb (g/dL)	13.19 ± 1.66
LVEF (%)	46.10 ± 11.00
Chronic stable angina	134 (18.10)
Acute coronary syndrome	606 (81.89)
STEMI	361 (48.78)
NSTEMI	80 (10.81)
Unstable angina	165 (22.29)
Hypertension	203 (27.43)
Diabetes mellitus	182 (24.59)
Smoking current	205 (27.70)
Previous stroke	7 (0.94)
Previous MI	48 (6.48)
Previous PCI	64 (8.64)
Previous CABG	7 (0.94)
Patients with renal dysfunction (eGFR < 60)	63 (8.51)

eGFR: Estimated glomerular filtration rate; Hb: Hemoglobin; LVEF: Left ventricular ejection fraction; STEMI: ST segment elevation myocardial infarction; NSTEMI: Non-ST segment elevation myocardial infarction; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; CABG: Coronary artery bypass graft.

Table 2 Angiographic and procedural characteristics

Angiographic feature/procedural characteristic	n (%)
Number of diseased vessels
Single vessel	310 (41.89)
Double vessel	276 (37.29)
Triple vessel	154 (20.81)
Patients having LMCA disease	37 (5.0)
Primary PCI	90 (12.16)
Post-procedure TIMI 3 flow	738 (99.7)
Lesion characteristics
Total number of lesions	1372
Total number of lesions treated with NeoHexa	911
Total number of lesions treated with other stents	118
Total number of lesions managed medically	343
Lesion location (for lesions treated with NeoHexa stent)
LAD	385 (42.26)
LCX	228 (25.03)
RCA	274 (30.07)
Others	24 (2.63)
Procedural characteristics
Total number of NeoHexa deployed	1317
Total number of other stents deployed	176
Lesion per patient	1.85 ± 1.06
Study stents deployed per patient	1.77 ± 1.1
Average length of study device, mm	21.90 ± 9.27
Average diameter of study device, mm	2.90 ± 0.42

LMCA: Left main coronary artery; PCI: Percutaneous coronary intervention; TIMI: Thrombolysis in myocardial infarction; LAD: Left anterior descending artery; LCX: Left circumflex artery; RCA: Right coronary artery.

Table 3 Cumulative clinical outcomes

Clinical events	n (%)
MACE	32 (4.32)
Cardiac death	19 (2.57)
TLR/TVR	13 (1.76)
Target vessel MI (without TLR/TVR or mortality)	0 (0.00)
Non-cardiac death	35 (4.73)
NYHA I/II without TLR/TVR	673 (90.95)

MACE: Major adverse cardiac event; TLR: Target lesion revascularization; TVR: Target vessel revascularization; MI: Myocardial infarction; NYHA: New York Heart Association.